Business Wire

ARM

22.6.2020 18:02:04 CEST | Business Wire | Press release

Share
Arm Technology Powers the World’s Fastest Supercomputer

Today at the International Supercomputing Conference (ISC) it was announced that the Fugaku supercomputer, a system jointly developed by RIKEN and Fujitsu Limited, and based on Arm® technology, was awarded the number one spot of the TOP500 list. Having been crowned the world’s most efficient supercomputer on the Green500 list in November 2019, Fugaku was today also given top honors on the HPCG list, a ranking of benchmarks across real-world applications, and the HPL-AI , which rates performance on tasks used in artificial intelligence applications.

“We are incredibly proud to see an Arm-based supercomputer of this scale come to life and thank RIKEN and Fujitsu for their commitment and collaboration,” said Rene Haas, president, IP Group, Arm. “Powering the world’s fastest supercomputer is a milestone our entire ecosystem should be celebrating as this is a significant proof point of the innovation and momentum behind Arm platforms making meaningful impact across the infrastructure and into HPC.”

This achievement represents for the industry a significant evolution in the needs of the modern infrastructure. Compute efficiency is more important than ever, developers are demanding more efficiency and flexibility, and the cloud is driving massive change across the ecosystem. Arm has answered the challenge with its Neoverse™ roadmap and portfolio which aims to deliver the performance, efficiency, and scalability required to enable the next generation of HPC deployments. Arm has also made significant investments across the HPC software ecosystem, enabling seamless migration across instruction sets, cross-platform development, profiling, and debug. Most recently, the company added additional porting capabilities to Arm Compiler for Linux and Arm Allinea Studio to help accelerate applications on current and future Arm CPUs, as more projects of this scale will be based on Arm because of its openness, efficiency, and software ecosystem maturity.

Today’s announcement signals the direction that industry is headed, and through this collaborative effort, a shared purpose of enabling greater choice and flexibility to multiple segments of the infrastructure market has emerged.

The Fugaku supercomputer, which is located at the RIKEN Center for Computational Science, is the flagship system designed to support a number of applications that will address both social and scientific issues as Japan works to achieve “Society 5.0 ”. Fugaku will accelerate research that spans drug discovery and weather and climate forecasting, to new production processes, and is already being used in the fight against COVID-19 to gain a better understanding of the novel coronavirus.

To learn more about Arm’s journey in HPC, visit the Arm Newsroom .

To read more about the Fugaku supercomputer, read here .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 13:00:00 CEST | Press release

Global brands including Bosch, Castrol, Coca-Cola Al Ahlia Beverages, and Moët Hennessy take the stage in Barcelona as Kinaxis sets the direction for the next era of supply chain Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat

Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 13:00:00 CEST | Press release

The Danish medtech company's ear-EEG platform can now be placed on the European market, enabling clinicians to record multi-day and multi-night EEG in the patient's home for epilepsy, sleep and other neurophysiological research and care. Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release

New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD)​ TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated

NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release

Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 12:00:00 CEST | Press release

Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platformLilly to make a strategic investment in QurCan QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboratio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye